Harvard Business School announces 2026-2027 Blavatnik Fellows
Harvard Business School (HBS) has named its 2026-27 Blavatnik Fellows. The fellowship offers HBS alumni and Harvard-affiliated postdoctoral researchers the opportunity to advance new life science technology ventures and develop their leadership talents during a 12-month fellowship year. To date, Blavatnik Fellows have founded 50 biomedical companies developing innovations including gene writing technologies, engineered cell therapies, oral biologic drug delivery platforms, AI-enabled digital health solutions, and therapeutics for cancer, neurological, and metabolic diseases. Collectively, Fellows have raised more than $800 million in private and public capital to advance their ventures.
Harvard Business School (HBS) has named its 2026-27 Blavatnik Fellows. The fellowship offers HBS alumni and Harvard-affiliated postdoctoral researchers the opportunity to advance new life science technology ventures and develop their leadership talents during a 12-month fellowship year. To date, Blavatnik Fellows have founded 50 biomedical companies developing innovations including gene writing technologies, engineered cell therapies, oral biologic drug delivery platforms, AI-enabled digital health solutions, and therapeutics for cancer, neurological, and metabolic diseases. Collectively, Fellows have raised more than $800 million in private and public capital to advance their ventures.
What's Your Reaction?
